NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages (Q37935278)

scientific article published on 03 September 2011

Language	Label	Description	Also known as
English	NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages	scientific article published on 03 September 2011

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

25 August 2017

1 reference

Europe PubMed Central

title

NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages (English)

1 reference

stated in

Europe PubMed Central

25 August 2017

0 references

1 reference

4

1 reference

stated in

Europe PubMed Central

25 August 2017

Veerle Bieghs

1

1 reference

stated in

Europe PubMed Central

PubMed ID

21930273

retrieved

25 August 2017

Patrick C N Rensen

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed ID

21930273

retrieved

25 August 2017

Marten H Hofker

series ordinal

3

1 reference

stated in

Europe PubMed Central

25 August 2017

3 September 2011

1 reference

stated in

Europe PubMed Central

25 August 2017

1 reference

Europe PubMed Central

25 August 2017

220

1 reference

stated in

Europe PubMed Central

25 August 2017

2

1 reference

stated in

Europe PubMed Central

25 August 2017

287-293

1 reference

stated in

Europe PubMed Central

25 August 2017

Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice

2 references

28 October 2023

https://opencitations.net/index/coci/api/v1/citations/10.1016/J.FEBSLET.2010.01.046

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Inflammation and atherosclerosis

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Lipotoxicity: when tissues overeat

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Hepatic steatosis is associated with an increased risk of carotid atherosclerosis.

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

A role of the bile salt receptor FXR in atherosclerosis

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

High-density lipoprotein as a therapeutic target: a systematic review

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice.

2 references

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

28 October 2023

https://opencitations.net/index/coci/api/v1/citations/10.1053/J.GASTRO.2010.02.051

Adipocytokines: mediators linking adipose tissue, inflammation and immunity

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Mechanisms linking obesity with cardiovascular disease

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

PPAR delta as a therapeutic target in metabolic disease.

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Recent concepts in non-alcoholic fatty liver disease

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Increased apoptosis in high-fat diet-induced nonalcoholic steatohepatitis in rats is associated with c-Jun NH2-terminal kinase activation and elevated proapoptotic Bax

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study.

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Oxidized low-density lipoprotein levels circulating in plasma and deposited in the tissues: comparison between Helicobacter pylori-associated gastritis and acute myocardial infarction

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Specific dietary polyphenols attenuate atherosclerosis in apolipoprotein E-knockout mice by alleviating inflammation and endothelial dysfunction.

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Lipoprotein retention--and clues for atheroma regression

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Steatohepatitis: a tale of two "hits"?

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Production of pro- and anti-fibrotic agents by rat Kupffer cells; the effect of octreotide

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Inflammation in atherosclerosis

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

The role of fenofibrate in clinical practice

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis

2 references

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

28 October 2023

https://opencitations.net/index/coci/api/v1/citations/10.1002/HEP.22363

Interleukin 6 is associated with subclinical atherosclerosis: a link with soluble intercellular adhesion molecule 1.

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Hepatocyte-specific IKKβ expression aggravates atherosclerosis development in APOE*3-Leiden mice

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Overproduction of large VLDL particles is driven by increased liver fat content in man.

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Circulating markers of inflammation and atherosclerosis

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Lysosomal accumulation of oxidized phosphatidylcholine-apolipoprotein B complex in macrophages: intracellular fate of oxidized low density lipoprotein

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

NASH predicts plasma inflammatory biomarkers independently of visceral fat in men

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Atherosclerosis. the road ahead

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Liver gene expression associated with diet and lesion development in atherosclerosis-prone mice: induction of components of alternative complement pathway.

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Feeding apolipoprotein E-knockout mice with cholesterol and fat enriched diets may be a model of non-alcoholic steatohepatitis

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Nonalcoholic fatty liver disease

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

A pilot trial of pentoxifylline in nonalcoholic steatohepatitis.

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

PPARdelta in humans: genetic and pharmacological evidence for a significant metabolic function

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Drug treatment of lipid disorders

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease.

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

The farnesoid X-receptor is an essential regulator of cholesterol homeostasis

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Scavenger receptors in atherosclerosis: beyond lipid uptake

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression.

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates

2 references

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

28 October 2023

https://opencitations.net/index/coci/api/v1/citations/10.1016/J.JHEP.2005.10.033

Apolipoprotein synthesis in nonalcoholic steatohepatitis

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Adipocytokines and insulin resistance

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Dendritic-cell genealogy

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

MiR-33 contributes to the regulation of cholesterol homeostasis.

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice.

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

p55 Tumour necrosis factor receptor in bone marrow-derived cells promotes atherosclerosis development in low-density lipoprotein receptor knock-out mice

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Endothelial dysfunction in Turkish patients with non-alcoholic fatty liver disease

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Role of mitochondria in non-alcoholic fatty liver disease

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Synthetic LXR ligand inhibits the development of atherosclerosis in mice

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Pleiotropic effects of statins

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease.

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Atherosclerotic mice exhibit systemic inflammation in periadventitial and visceral adipose tissue, liver, and pancreatic islets.

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease.

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Novel treatment modalities for nonalcoholic steatohepatitis

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Absence of CD36 protects against atherosclerosis in ApoE knock-out mice with no additional protection provided by absence of scavenger receptor A I/II

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S).

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

TNF-alpha decreases ABCA1 expression and attenuates HDL cholesterol efflux in the human intestinal cell line Caco-2

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Subendothelial retention of atherogenic lipoproteins in early atherosclerosis

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Integration of metabolism and inflammation by lipid-activated nuclear receptors

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH.

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Non-alcoholic steatohepatitis: another disease of affluence

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Association between postprandial LDL conjugated dienes and the severity of liver fibrosis in NASH

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Carotid artery intima-media thickness in nonalcoholic fatty liver disease

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Inflammation and insulin resistance

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E.

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Endothelial dysfunction: a marker of atherosclerotic risk

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E.

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

The pathogenesis of atherosclerosis: a perspective for the 1990s

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes

1 reference

28 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2011.08.041

Identifiers

DOI

10.1016/J.ATHEROSCLEROSIS.2011.08.041

1 reference

stated in

Europe PubMed Central

25 August 2017

1 reference

Europe PubMed Central

PubMed ID

21930273

retrieved

25 August 2017

ResearchGate publication ID

51654563

0 references

NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages (Q37935278)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages (Q37935278)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

Search